Murepavadin

Drug Profile

Murepavadin

Alternative Names: POL 7080; RG 7929

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Polyphor; University of Zurich
  • Developer Polyphor
  • Class Antibacterials; Cyclic peptides
  • Mechanism of Action Imp protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pseudomonal infections
  • Phase I Gram-negative infections

Most Recent Events

  • 01 Jun 2017 Polyphor plans a phase III program for Pseudomonal infections, in the second half of 2017
  • 31 Jan 2017 Polyphor terminates a phase II trial for Pseudomonal infections in Germany, Spain and United Kingdom (NCT02096315)
  • 01 Dec 2016 Polyphor completes a phase I drug-drug interaction trial in Healthy volunteers in Germany (IV) (NCT02897869)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top